Satralizumab Clinical Trials
4 recruitingDrug
Phase 33Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NMDAR Autoimmune EncephalitisLGI1 Autoimmune Encephalitis
Hoffmann-La Roche152 enrolled93 locationsNCT05503264
Recruiting
Phase 3
A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum DisorderNMOSD
Hoffmann-La Roche8 enrolled13 locationsNCT05199688
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche152 enrolled82 locationsNCT05271409
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Hoffmann-La Roche50 enrolled25 locationsNCT06450639